Cargando…

Dose-Ranging Study of Ramosetron for the Prevention of Nausea and Vomiting after Laparoscopic Gynecological Surgery: A Prospective Randomized Study

Patients undergoing laparoscopic gynecologic surgery and receiving postoperative analgesia with opioids have a high risk of postoperative nausea and vomiting (PONV). We compared the antiemetic efficacy of three doses of ramosetron in this high-risk population. In this prospective, double-blind trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Jin Sun, Kim, Sang Wun, Lee, Sugeun, Yoo, Young Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947581/
https://www.ncbi.nlm.nih.gov/pubmed/31835896
http://dx.doi.org/10.3390/jcm8122188
_version_ 1783485583440478208
author Cho, Jin Sun
Kim, Sang Wun
Lee, Sugeun
Yoo, Young Chul
author_facet Cho, Jin Sun
Kim, Sang Wun
Lee, Sugeun
Yoo, Young Chul
author_sort Cho, Jin Sun
collection PubMed
description Patients undergoing laparoscopic gynecologic surgery and receiving postoperative analgesia with opioids have a high risk of postoperative nausea and vomiting (PONV). We compared the antiemetic efficacy of three doses of ramosetron in this high-risk population. In this prospective, double-blind trial, 174 patients randomly received ramosetron 0.3 mg (R0.3 group; n = 58), 0.45 mg (R0.45 group; n = 58), or 0.6 mg (R0.6 group; n = 58) at the end of surgery. The primary outcome was the incidence of PONV during the first postoperative 48 h. Nausea severity, pain scores, adverse events, and patient satisfaction (1–4; 4, excellent) were assessed. The incidence of PONV was not different between groups (35%, 38%, and 35% in R0.3, R0.45, and R0.6 groups; p = 0.905). Nausea severity, pain scores, and incidence of adverse events (dizziness, headache, or sedation) were similar between groups. Compared to the R0.3 group, the R0.45 and R0.6 groups had lower incidence of premature discontinuation of fentanyl-based patient-controlled analgesia primarily because of intractable PONV (9% and 5% vs. 24%; p = 0.038), and higher satisfaction scores (3.4 ± 0.8 and 3.3 ± 0.7 vs. 2.4 ± 0.9; p = 0.005). Compared to ramosetron 0.3 mg, ramosetron 0.45 and 0.6 mg did not reduce PONV, but reduced premature discontinuation of patient-controlled analgesia and increased patient satisfaction, without increasing adverse events.
format Online
Article
Text
id pubmed-6947581
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69475812020-01-13 Dose-Ranging Study of Ramosetron for the Prevention of Nausea and Vomiting after Laparoscopic Gynecological Surgery: A Prospective Randomized Study Cho, Jin Sun Kim, Sang Wun Lee, Sugeun Yoo, Young Chul J Clin Med Article Patients undergoing laparoscopic gynecologic surgery and receiving postoperative analgesia with opioids have a high risk of postoperative nausea and vomiting (PONV). We compared the antiemetic efficacy of three doses of ramosetron in this high-risk population. In this prospective, double-blind trial, 174 patients randomly received ramosetron 0.3 mg (R0.3 group; n = 58), 0.45 mg (R0.45 group; n = 58), or 0.6 mg (R0.6 group; n = 58) at the end of surgery. The primary outcome was the incidence of PONV during the first postoperative 48 h. Nausea severity, pain scores, adverse events, and patient satisfaction (1–4; 4, excellent) were assessed. The incidence of PONV was not different between groups (35%, 38%, and 35% in R0.3, R0.45, and R0.6 groups; p = 0.905). Nausea severity, pain scores, and incidence of adverse events (dizziness, headache, or sedation) were similar between groups. Compared to the R0.3 group, the R0.45 and R0.6 groups had lower incidence of premature discontinuation of fentanyl-based patient-controlled analgesia primarily because of intractable PONV (9% and 5% vs. 24%; p = 0.038), and higher satisfaction scores (3.4 ± 0.8 and 3.3 ± 0.7 vs. 2.4 ± 0.9; p = 0.005). Compared to ramosetron 0.3 mg, ramosetron 0.45 and 0.6 mg did not reduce PONV, but reduced premature discontinuation of patient-controlled analgesia and increased patient satisfaction, without increasing adverse events. MDPI 2019-12-11 /pmc/articles/PMC6947581/ /pubmed/31835896 http://dx.doi.org/10.3390/jcm8122188 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cho, Jin Sun
Kim, Sang Wun
Lee, Sugeun
Yoo, Young Chul
Dose-Ranging Study of Ramosetron for the Prevention of Nausea and Vomiting after Laparoscopic Gynecological Surgery: A Prospective Randomized Study
title Dose-Ranging Study of Ramosetron for the Prevention of Nausea and Vomiting after Laparoscopic Gynecological Surgery: A Prospective Randomized Study
title_full Dose-Ranging Study of Ramosetron for the Prevention of Nausea and Vomiting after Laparoscopic Gynecological Surgery: A Prospective Randomized Study
title_fullStr Dose-Ranging Study of Ramosetron for the Prevention of Nausea and Vomiting after Laparoscopic Gynecological Surgery: A Prospective Randomized Study
title_full_unstemmed Dose-Ranging Study of Ramosetron for the Prevention of Nausea and Vomiting after Laparoscopic Gynecological Surgery: A Prospective Randomized Study
title_short Dose-Ranging Study of Ramosetron for the Prevention of Nausea and Vomiting after Laparoscopic Gynecological Surgery: A Prospective Randomized Study
title_sort dose-ranging study of ramosetron for the prevention of nausea and vomiting after laparoscopic gynecological surgery: a prospective randomized study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947581/
https://www.ncbi.nlm.nih.gov/pubmed/31835896
http://dx.doi.org/10.3390/jcm8122188
work_keys_str_mv AT chojinsun doserangingstudyoframosetronforthepreventionofnauseaandvomitingafterlaparoscopicgynecologicalsurgeryaprospectiverandomizedstudy
AT kimsangwun doserangingstudyoframosetronforthepreventionofnauseaandvomitingafterlaparoscopicgynecologicalsurgeryaprospectiverandomizedstudy
AT leesugeun doserangingstudyoframosetronforthepreventionofnauseaandvomitingafterlaparoscopicgynecologicalsurgeryaprospectiverandomizedstudy
AT yooyoungchul doserangingstudyoframosetronforthepreventionofnauseaandvomitingafterlaparoscopicgynecologicalsurgeryaprospectiverandomizedstudy